Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial

Lancet

Volumn 356, Issue 9223, 2000, Pages 9-16

  Wallentin, Lars ^a   Lagerqvist, Bo ^a   Husted, Steen ^b   Kontny, Frederic ^c   Ståhle, Elisabet ^a   Swahn, Eva ^d  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AKER UNIVERSITY HOSPITAL   (Norway)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DALTEPARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAPHY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVASCULARIZATION; TREATMENT OUTCOME; ANGIOCARDIOGRAPHY; COMPARATIVE STUDY; DISEASE COURSE; DISEASE MANAGEMENT; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DALTEPARIN; DISEASE MANAGEMENT; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034222936     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(00)02427-2     Document Type: Article

References (28)

1. Theroux P, Fuster V. Acute coronary syndromes, unstable angina and non-Q-wave myocardial infarction. Circulation 1998; 97: 1195-206.
2. FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 708-15.
3. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial: a randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q-wave myocardial infarction. J Am Coll Cardiol 1995; 26: 1643-50.
4. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy: Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial. N Engl J Med 1998; 338: 1785-92.
5. FRISC II Investigators. Long-term low molecular mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701-07.
6. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
7. Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996; 276: 811-15.
8. Turpie AGG. Clinical trials of low molecular mass heparin. Am J Cardiol 1999; 1: R18-27.
9. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-35.
10. PRISM PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
11. PURSUIT Trial Investigators. Inhibition of platelet glycoprotien IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
12. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 11-322.
13. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Trialists Collaboration. Lancet 1994; 344: 563-67.
14. Varnauskas E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med 1988; 319: 332-37.
15. RITA2 trial participants. Coronary angioplasty versus medical treatment for angina: the second randomised intervention treatment of angina. Lancet 1997; 350: 461-68.
16. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). ACC/AHA Guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol 1996; 28: 1328-428.
17. Uretsky BF, Runge MS. Unstable angina. Cardiol Clin 1999; 17: 247-437.
18. OASIS-2. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999; 353: 429-38.
19. GUSTO lib. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82.
20. Abdelmeguid AE, Topol EJ. The myth of the myocardial infarctlet during percutaneous coronary revascularisation procedures. Circulation 1996; 94: 3369-75.
21. Simoons ML, van den Brand M, Lincoff M, et al. Minimal myocardial damage during coronary intervention is associated with impaired outcome. Eur Heart J 1999; 20: 1112-19
22. Kolli AK, Dai H, Hlatky MA, et al. Quality of life comparisons in non-Q-wave MI patients randomized to an early invasive vs. conservative strategy: results of the VA Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial. J Am Coll Cardiol 1999; 33 (suppl A): 397 (abstr).
23. Fragmin During Instability In Coronary Artery Disease Study Group. Low molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-68.
24. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study. Circulation 1997; 96: 61-68.
25. FRAX.I.S. trialists. Comparison of two treatment durations (6 days and 14 days) of a low molecular mass heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction. Eur Heart J 1999; 20: 1553-62.
26. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-52.
27. PRISM Study Investigators. A comparison of aspirin plus tirofiban versus aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505.
28. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-601.